Foreign Bodies ; surgery ; Head ; Humans ; Imaging, Three-Dimensional ; Jaw Fractures ; surgery ; Maxillofacial Injuries ; diagnostic imaging ; surgery ; Radiography, Dental, Digital ; Surgery, Computer-Assisted ; Tomography, X-Ray Computed

OBJECTIVE:To prepare the scutellarin-PEG-PLGA drug-laded nanoparticles,optimize the formulation with ratio of colostrum and external aqueous phase,mass concentration of scutellarin and PEG-PLGA as factors and conduct quality evalua-tion. METHODS:A double emulsion-solvent evaporation method was adopted to prepare the scutellarin-PEG-PLGA nanoparticles. With the evaluation index of encapsulation efficiency,single factor and orthogonal test were used to determine the apparent shape, particle size,Zeta potential,drug loading amount,encapsulation efficiency and stability of prepared nanoparticles by optimized for-mulation with ratio of colostrum and external aqueous phase,mass concentration of scutellarin and PEG-PLGA as factors. RE-SULTS:The ratio of colostrum and external aqueous phase was 1∶15 and the mass concentrations of scutellarin and PEG-PLGA were respectively 10 mg/ml and 15 mg/ml in optimized formulation;the prepared nanoparticles were round or oval with the average particle size of(78.54±2.21)nm,Zeta potential of(-23.07±1.39)mV,drug loading amount of(1.67±0.12)%,and encapsula-tion efficiency of(45.32±1.29)%. There was no obvious changes in the particle size and encapsulation efficiency within 3 months at 4 ℃ preservation. CONCLUSIONS:The scutellarin-PEG-PLGA nanoparticles with better physical and chemical properties and stability are successfully prepared.

Ankylosis ; etiology ; Humans ; Mandibular Condyle ; injuries ; Mandibular Fractures ; complications ; Temporomandibular Joint Disc ; injuries ; Temporomandibular Joint Disorders ; etiology

Humans ; Mandibular Condyle ; injuries ; surgery ; Mandibular Fractures ; complications ; surgery

Environmental Exposure ; prevention & control ; Environmental Monitoring ; Humans ; Occupational Health Services ; organization & administration

Purpose: Introduce the way of the treatment of deep veinous thrombosis of leg. Meerials and Methods: 26 patients (27 legs) refred for phlebothrombosis of leg, were prove by lower limb Phlebography or ECT. 100～200 thousand unit UK was infused through dorsal veins of sick leg, once or twice per day with 7 days a coure of treatment. Results: 17of 27 legs with phlebothromb0sis, were cured the successful rate 63%, 8 were improved, 30%; 2 were noneffective, 7%. No bleeding occurred 1 case of pulmonary segment embolism. Conclusion The way of the treatment of lower limb deep vein thrombosis by infusion of UK from dorsal veins of sick foot is safe and reliable.

Objective To evaluate the effect of alIoHCT on recurrence and metastasis of HCC after hepatic radical resection. Methods Umbilical cord blood were collected after labor. The efficacy of separa-tion by 6% hydroxyethyl starch (6% HES) and NH4CL lysing solution were examined. Twenty-two SCID mice were randomized into the scheduled transplantation group (n=8), the single transplantation group (n =8) and the normal saline group (n=6). Human nucleated cells (NC)at a amount of 5×107 were transfused through the tail vein into the 2 groups of transplantation. All the mice in the 3 groups received cyclophospha-mide (CTX) as conditioning regimen before tansplantation and Methylprednisolone (MP) for 1 week continu-ously after trasplantation. Hematopoietic and immune recovery, graft versus host disease (GVHD), engraft-ment and survival rate were observed after transplantation. Six weeks after alloHST, the orthotopic tumor model in SCID mice was established by implanting histologically intact tissue under the embrane of liver. Ten days later, the mice received radical resection of lobe bearing tumor. The condition of recurrence and metas-tasis was observed 4 weeks after operation. Results A murine model of umbilical cord blood transplantation using CTX and MP as conditioning regimen could be successfully established in SCID mice. The percentage CD34+ cells of peripheral blood NC in scheduled transplantation group and single transplantation group was 1.66%±0.47% and 0.68% + 0.56%, respectively. There was significant statistical significance (P<0.01). The intrahepatic recurrence rate after operation was 100% in all the 3 groups. However, the recur-rent tumor volume was (367.18±31.86) mm3 , (648.26±155.22) mm3, (811.38±127.36) mm3, re-spectively in the 3 groups. There was marked difference among the 3 groups (P<0.01). The inhibitory rate of group A and B was 54.7% and 20.1%. The incidence of lung metastasis was 14.3 (1/7), 6.7% (4/6) and 100% (5/5), respectively in the 3 groups and there was remarkable difference (P<0.01). The inci-dence of celiac lymph node metastasis was 14.3 (1/7), 33.4% (2/6) and 40% (2/5), respectively in the 3groups and there was no significant difference (P=0.58). Conclusion AlloHSCT is a useful method for de-creasing metastasis and recurrence of liver cancer after radical resection in early stage.

Bone Plates ; Computer-Aided Design ; Fracture Fixation, Internal ; instrumentation ; methods ; Humans ; Radiography ; Surgery, Computer-Assisted ; Zygomatic Fractures ; diagnostic imaging ; surgery

Objective: To investigate the clinical efficacy of nalmefene hydrochloride in the treatment of patients with traumatic shock. Methods:Totally 62 cases of patients with traumatic shock were randomly divided into nalmefene treatment group (n=31) and the control group ( n =31 ) according to the random number table. The control group was given the conventional treatment, while nalmefene treatment group was treated with nalmefene hydrochloride additionally. The changes of hemodynamics, plasma TNF-αand vas-cular endothelial function index were compared between the groups. Results:The mean arterial pressure in 24h after the treatment signifi-cantly decreased when compared with that in 12h after the treatment of nalmefene treatment group, and the difference was statistically sig-nificant (P<0. 05);the heart rate in 12h and 24h after the treatment in nalmefene treatment group significantly decreased when com-pared with that before the treatment, and the differences were statistically significant (P<0. 05);the plasma TNF-αlevels in 24h after the treatment in nalmefene treatment group significantly decreased when compared with that in 12h after the treatment, and the difference was statistically significant (P<0. 05), and there was no significant difference in plasma TNF-α levels before the treatment and in 12h after the treatment (P<0. 05);the plasma NO and ET in 24h after the treatment in nalmefene treatment group significantly decreased when compared with that in 12h after the treatment, and the difference were statistically significant (P<0. 05);and there was no signifi-cant difference in plasma NO and ET before the treatment and in 24h after the treatment (P<0. 05);abnormality in electrocardiogram, routine blood tests, routine urine and liver and renal function examinations were not found, and no obvious adverse drug reactions were shown during the treatment course. Conclusion:Nalmefene hydrochloride combined with the conventional treatment in the patients with traumatic shock shows striking efficiency with notable effects on hemodynamics ( heart rate and mean arterial pressure) , which can reduce plasma TNF-α, NO and ET levels and shows significant research significance.

Objective To evaluate the efficacy and safety of simulect (basiliximab) after orthotopic liver transplantation (OLT). Methods Forty adult recipients with benign end-stage liver disease between November 2003 to November 2004 were assigned randomly in a 1∶1 ratio to receive either two doses of simulect or matching placebo. The patients in the two groups received baseline triple immunosuppression with the calcineurin inhibitor (CsA or FK506), MMF and steroids. A total of 40 mg simulect was given in two doses of 20 mg each on the day 0 before inferior vena was opened and the day 4 after transplantation respectively. Acute rejection, infection and serum ALT, AST, TBIL, DBIL and ALP in both groups were observed in the first 30 days after OLT. Results In Simulect group had less frequent incidence of acute refection during the first 30 days after OLT. In Simulect group and matching placebo, incidence of acute refection was 10 % (2/20) abd 45 % (9/20) respectively (P= 0.034), and that of infection was 40 % (8/20) and 45 % (9/20) respectively (P= 0.749). Bilirub and aminopherase in both groups were declined gradually and ALP increased. There were significant difference in ALT and TBIL between two groups. Conclusion The application of simulect in combination with CsA/FK506, MMF and prednisone is safe and well tolerated, and can effectively reduce the incidence of acute refection, and does not lead to increased opportunistic infections.